Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: A multicenter, retrospective case series

Sowmya Ravi, Johns Hopkins University
Kristen Spencer, Rutgers Cancer Institute of New Jersey
Mary Ruisi, Bristol-Myers Squibb
Nageatte Ibrahim, Harvard Medical School
Jason J. Luke, Harvard Medical School
John A. Thompson, University of Washington
Keisuke Shirai, Medical University of South Carolina
David Lawson, Emory University
Heddy Bartell, Bristol-Myers Squibb
Ragini Kudchadkar, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal for ImmunoTherapy of Cancer
Volume: Volume 2
Publisher: BioMed Central | 2014-10-14
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/s40425-014-0033-1
Permanent URL: https://pid.emory.edu/ark:/25593/s1r4p

Final published version: http://dx.doi.org/10.1186/s40425-014-0033-1

Copyright information:
© Ravi et al.; licensee BioMed Central Ltd. 2014
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed October 24, 2024 5:29 PM EDT
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert, and Evan J Lipson

Abstract

Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potentially serious immune-related adverse events, including autoimmune hepatitis. Because clinical trials of ipilimumab excluded patients with pre-existing hepatitis B or C infection, there is a paucity of data on the safety of ipilimumab administration to that patient population. Here, we report the largest case series to date of patients with hepatitis B or C who received ipilimumab for advanced melanoma. Two of the nine patients described in this case series experienced fluctuations in their liver function tests (LFTs) and were subsequently treated with corticosteroids. Although this is a small series, the rate of hepatotoxicity appears similar to what has been seen in the general population treated with ipilimumab, and the ability to administer ipilimumab did not appear to be affected by concomitant hepatitis B or C infection. The use of ipilimumab in patients with metastatic melanoma who have pre-existing hepatitis can be considered among other therapeutic options.

Keywords: Ipilimumab, Melanoma, Hepatitis B, Hepatitis C

Background

The US Food and Drug Administration’s approval of ipilimumab (Yervoy, Bristol-Myers Squibb, Princeton, NJ) in 2011 heralded a new era in the treatment of advanced melanoma. A fully human monoclonal antibody against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), ipilimumab demonstrated a survival benefit and durable disease control in randomized, controlled phase III clinical trials [1-3]. However, those trials and others performed during the pre-marketing drug development of ipilimumab excluded patients with pre-existing hepatitis B or C. Moreover, ipilimumab administration is associated with serious (grade 3/4) adverse events with potential immune-related causality, including autoimmune hepatitis. Although the risk of reactivation of hepatitis B (HBV) or C (HCV) in infected patients is well-described in patients receiving cytotoxic chemotherapy [4,5], there is a paucity of data on the safety of administering ipilimumab or other immunotherapies to that patient population [6,7]. Here, we report the largest case series to date of patients with hepatitis B or C who received ipilimumab for advanced melanoma. All patients received ipilimumab at the FDA-approved dose of 3 milligrams per kilogram of body weight. Cases are described in detail below and are summarized in Table 1.

Case presentations

Case 1: A 65-year-old man presented with metastatic melanoma involving his lungs and mediastinal and neck lymph nodes; he had no detectable hepatic metastases. The patient had contracted HCV (genotype 1a) approximately
| Case No. | Age (yrs) | Sex | Liver metastases? | Type of Hepatitis | Evidence of liver fibrosis? | Therapy for metastatic melanoma prior to ipilimumab | LFTs prior to administration of ipilimumab | Change in LFTs during Ipilimumab | Best Response to Ipi | Comments |
|---------|-----------|-----|-------------------|-------------------|-----------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------|------------------|----------|
| 1       | 65        | M   | N                 | HCV (active)      | Y                           | High dose Interleukin-2                        | Gr 1 AST, Gr 1 ALT                        | None                            | PD                | HCV viral load increased four-fold after IL-2, ipilimumab and temozolomide |
| 2       | 56        | M   | N                 | HCV (active)      | Unknown                     | Stereotactic Radiotherapy, then WBRT          | AST & ALT WNL                              | None                            | PD                | Possible drug-related hepatitis detected 2 months after receiving 4 doses of ipilimumab |
| 3       | 43        | M   | N                 | HCV (active)      | N                           | Temozolomide                                  | Gr 2 AST, Gr 2 ALT                        | Normalized by cycle 4            | Mixed response | HCV viral load decreased to undetectable levels after 4 doses of ipilimumab |
| 4       | 71        | M   | N                 | HCV (active)      | Y                           | None                                         | Gr 1 AST, Gr 1 ALT                        | Gr 2 AST, Gr 3 ALT after cycle 3 | SD                | HCV viral load decreased 5-fold to 408,000 IU/mL after 3 doses of ipilimumab; ocular melanoma |
| 5       | 56        | M   | (multiple tumors involving 25-75% of liver, largest = 6.4 cm) | HBV (inactive)     | Unknown                     | None                                         | Gr 1 AST, ALT WNL                          | None                            | PD                | Concurrent administration of entecovir for prophylaxis against HBV reactivation |
| 6       | 60        | M   | N                 | HBV (active)      | Unknown                     | high-dose Interleukin-2, talimogene laherparepvec and dacarbazine | AST & ALT WNL                              | None                            | PD                | Tenofovir administration prior to ipi brought HBV viral load from 2950 to 41 IU/mL; became undetectable and remained so throughout ipilimumab |
| 7       | 42        | F   | (multiple tumors involving 30-40% of liver, largest = 2.7 cm) | HBV (inactive)     | Unknown                     | None                                         | AST & ALT WNL                              | None                            | PD                | HBV viral load undetectable prior to starting ipilimumab |
| 8       | 56        | M   | N                 | HBV (active)      | Unknown                     | None                                         | AST & ALT WNL                              | None                            | PD                | Entecavir administration prior to ipi brought HBV viral load from 9560 to 454 IU/mL; became undetectable and remained so throughout ipilimumab |
| 9       | 71        | M   | N                 | HBV (active)      | Cirrhosis noted on CT, no confirming path findings | None                                         | Gr 1 AST, ALT WNL                          | None                            | SD                | HBV viral load 700 IU/mL prior to starting ipilimumab |

Table 1 (Gr, Grade of toxicity as measured by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; AST, aspartate aminotransferase; ALT, Alanine aminotransferase; LFT, Liver function tests; PD, Progressive disease; Ipi, ipilimumab; SD, Stable disease).
twenty five years prior to his melanoma diagnosis, though his hepatitis was never treated. A liver biopsy performed in 2000 demonstrated periportal fibrosis without bridging as well as mild inflammatory activity. Pathologic findings from a repeat liver biopsy in 2005 were unchanged. His melanoma was initially treated with high-dose interleukin-2 (IL-2) in May 2011. After two cycles, his melanoma had regressed, but he developed obstructive jaundice secondary to cholelithiasis with gallbladder sludge, requiring a laparoscopic cholecystectomy. Serologic evaluation around the time of surgery (August 2011) revealed the following: HCV viral load: 690,000 IU/mL, hepatitis A IgM negative, HBV core (HBc) IgG and IgM negative, hepatitis B surface antigen (HBsAg) negative. A liver biopsy performed during surgery revealed cirrhosis with mild, non-specific inflammation and focal hemosiderin accumulation. He received two more cycles of IL-2, but his melanoma subsequently progressed and he began treatment with ipilimumab in November 2011. During and after ipilimumab administration, hepatic transaminases remained unchanged from baseline, with grade 1 elevations. Although the patient tolerated 4 cycles of ipilimumab without drug-limiting toxicities, he experienced disease progression and was transitioned to temozolomide. After three cycles of temozolomide, HCV viral load had increased four-fold to 2,720,000 IU/mL. The patient expired sixteen months after initiating ipilimumab, HCV viral load was >69,000,000 IU/mL, however, his hepatic transaminase levels subsequently normalized. Although his viral load and LFTs were discordant, the patient was approaching hospice care at this time and further investigation of the significance of these findings was postponed. Two months later, the patient died from progressive melanoma. Of note, this case was previously reported in detail but summarized here to augment the current case series [7].

Case 3: A 43-year-old man presented with metastatic melanoma involving axillary, hilar and pericardiac lymph nodes and soft tissue adjacent to the umbilicus, but no hepatic lesions. He was treated with six cycles of temozolomide, during which liver transaminases became elevated: AST 85 IU/L (normal 8-48 IU/L), ALT 164 IU/L (10-40 IU/L). The transaminitis persisted after discontinuation of temozolomide. An abdominal computed tomography (CT) scan showed no evidence of intra-abdominal metastases or hepatic cirrhosis; however serologies revealed HCV with a viral load of 398,938 IU/mL, genotype 1a. The patient tolerated four cycles of ipilimumab from April 2012 to July 2012 without interruption or complication. He had a mixed response to ipilimumab, but never progressed. Hepatic transaminases normalized by cycle 4, and HCV viral load was detectable at <12 IU/mL approximately four weeks later. Post-therapy the patient’s viral load began to climb: 1,378 IU/mL at eight weeks and 1,558 IU/mL at fourteen weeks after the fourth cycle of ipilimumab was administered. A remaining melanoma lesion in the right hilum was irradiated, and subsequent imaging with positron emission tomography (PET)/CT in January 2014 and CT in July 2014 demonstrated no evidence of disease. Since completing ipilimumab, HCV viral load has remained stable with normal LFTs. Of note, this case was previously reported in detail but summarized here to expand the current case series [6].

Case 4: A 71-year-old man presented with metastatic ocular (choroidal) melanoma without hepatic involvement. His primary lesion had been treated thirteen years earlier with right orbital enucleation. Three years after enucleation he was diagnosed with HCV but did not require treatment. Evaluations for hepatitis A, HBV and HIV were negative. Serologic evaluation prior to initiation
of ipilimumab revealed HCV viral load of 2,310,000 IU/mL and grade 1 AST and ALT. Three weeks after one cycle of ipilimumab, the patient was found to have grade 2 and 3 elevations of AST and ALT, respectively. Ipilimumab was held and high-dose prednisone was administered. HCV viral load had decreased to 408,000 IU/mL. Liver biopsy demonstrated chronic, active Scheuer grade 2 hepatitis and Scheuer stage 2 perportal fibrosis. There was no evidence of associated autoimmunity; a panel of serologic markers associated with autoimmune hepatitis (anti-nuclear cytoplasmic antibody, IgG; double stranded DNA antibody, IgG; F-actin antibody, IgG; anti-soluble liver antigen, IgG; mitochondrial M2 antibody, IgG; liver kidney microsome antibody; and anti-neuronal nuclear antigen, IgG; mitochondrial M2 antibody, IgG; liver kidney microsome antibody; and anti-neuronal nuclear antibody) was negative. Extractable nuclear antigen screen was equivocal and was not pursued. His serum IgG was mildly elevated at 1630 mg/dL (normal range 694-1,618). As there was no evidence of autoimmune hepatitis, his prednisone was discontinued. Magnetic resonance imaging (MRI) of the abdomen revealed no evidence of malignancy. The patient's ALT and AST returned to grade 1, and, after a brief dose delay, ipilimumab was restarted with subsequent normalization of hepatic transaminases. Five months after initiation of ipilimumab the patient's melanoma was stable and HCV viral load was 108,000 IU/mL. Eight months after initiation of ipilimumab, however, a bronchoscopy and PET/CT scan both showed progression of disease without hepatic involvement. Shortly thereafter, serum AST and ALT became elevated (grade 1). HCV viral load measured 11 months after initiation of ipilimumab increased to 653,000 IU/mL. The patient was treated with temozolomide, which was discontinued due to thrombocytopenia. He subsequently relocated and was lost to follow-up.

Case 5: A 56-year-old man with a history of HBV presented with stage IV melanoma involving the liver (multiple tumors, largest = 6.4 cm), pancreas, kidney, bones and mediastinal lymph nodes. At the time of ipilimumab administration, the patient's serum AST was 61 IU/L (normal range = 8-48) and ALT was normal at 25 IU/L. His bilirubin was mildly elevated at 1.57 mg/dL (0.1-1.2). Serologies revealed the following: HBSAg negative; HBV DNA undetectable by polymerase chain reaction (PCR); HBe negative; reactive Hepatitis B e-Antibody (anti-HBe), non-reactive Hepatitis B e-Antigen (HBeAg), and HBV viral load of 43,100 IU/mL. Without intervening therapy, HBV viral load fell to 2,950 IU/mL ten days later. Tenofovir therapy was initiated. After four months of treatment the patient's viral load was 41 IU/mL. Four cycles of ipilimumab were administered, which were well-tolerated and produced no LFT abnormalities. One month later, HBV viral load was undetectable. The patient expired four months after initiation of ipilimumab from progressive melanoma. Of note, this case was previously reported in detail but summarized here to expand the current case series [7].

Case 7: A 42-year-old Vietnamese woman, who had undergone resection of a mucosal (anal) melanoma two years earlier, presented with metastatic melanoma involving liver and bone. Serologies prior to treatment with ipilimumab revealed an undetectable HBV DNA by PCR, a negative HBeAg and positive anti-HBe, indicating viral exposure and clearance. Liver function studies were within normal limits prior to initiation of ipilimumab and remained normal throughout all 4 cycles of therapy. Though the patient did not experience any ipilimumab-related toxicity, radiologic scans performed one month after the final cycle demonstrated progression of disease.

Case 8: A 56-year-old Venezuelan man with HBV, who had previously received adjuvant IFNα after resection of a primary melanoma (cKIT mutant), presented with metastatic disease including pancreatic and splenic metastases. Prior to the initiation of ipilimumab, the patient's HBV DNA level was 9560 IU/mL with normal liver function tests. The patient stated that he had a liver biopsy in South America which was within normal limits; however this was not confirmed by repeat liver biopsy, although his radiographic imaging from the US does not show evidence of fibrosis. The patient was administered entecavir 0.5 mg daily, after which the viral load fell to 454 IU/mL. Ipilimumab was initiated 2 weeks later and entecavir was continued. The patient's viral load became undetectable, and his LFTs remained within normal limits throughout the course of treatment. Although
he completed 4 cycles of ipilimumab without significant complications, post-therapy radiologic scans demonstrated progressive disease. He was subsequently treated with temozolomide, then nilotinib, again without hepatic complications.

Case 9: A 71-year-old man presented with stage IV melanoma. He had received adjuvant IFNα after his initial melanoma diagnosis and surgical resection seven years prior, which coincided with a diagnosis of HBV. Hepatic transaminases prior to administration of IFNα were normal, though IFNα was held several times due to grade 2 and 3 elevations of ALT and AST. Three years prior to administration of ipilimumab, the patient was initiated on HBV treatment with tenofovir after serologic markers revealed a HBV viral load of >200,000,000 IU/mL and CT imaging demonstrated cirrhotic morphology and small volume ascites. One year into tenofovir therapy, HBV viral load had decreased to 1900 IU/mL. Two years later, laboratory evaluation immediately prior to initiation of ipilimumab revealed normal ALT, grade 1 elevation of AST and HBV viral load of 700 IU/mL. Hepatic transaminases remained stable throughout ipilimumab induction therapy, which resulted in stable disease for seven months. The patient’s melanoma then progressed, which was again treated with ipilimumab. ALT remained normal, AST remained grade 1; however the patient’s melanoma progressed five months later with no evidence of hepatic involvement. The patient remains on tenofovir at the time of this publication.

Conclusions

Although ipilimumab has undergone extensive clinical testing in patients with melanoma [8], its use in patients with infectious co-morbidities remains poorly characterized. Patients bearing similarity to the population broadly studied during clinical development often receive all four cycles of ipilimumab without evidence of autoimmune toxicity. However, other patients experience adverse events with potential immune-related causality, [otherwise “immune-related adverse events”] that can be dose limiting and cause significant morbidity [9]. Indeed, the two large phase III trials conducted prior to the drug’s approval by the FDA excluded patients receiving immunosuppressive medications, those with conditions requiring the long-term use of systemic corticosteroids and those with acute or chronic viral hepatitis. Since the side effect profile observed with ipilimumab differs significantly from that of standard cytotoxic chemotherapy due to its unique mechanism of action, understanding its relative safety in patients with hepatitis infection is crucial in helping to establish treatment guidelines. This is especially important in light of the fact that immune-mediated hepatotoxicity, a known adverse effect of ipilimumab, is of particular concern in patients with concomitant viral hepatitis. This concern arises from the theoretical risk of hepatitis B/C reactivation and the potential for immune-mediated liver damage in patients whose hepatic function may be compromised at baseline.

Chemotherapy-induced reactivation of hepatitis B or C that results in significant hepatic decompensation is well described [4,5]. Higher serum viral load prior to the initiation of therapy may influence risk of reactivation, and high pretreatment HBV DNA levels have been shown to correlate with poor tolerance to cytotoxic chemotherapy [10,11]. Several of these issues are being investigated in ongoing clinical trials. (NCT01658878) A theoretical risk of viral reactivation exists with the use of ipilimumab because of the presence of CTLA-4 on T regulatory (Treg) cells. This sub-population of immunoregulatory T cells suppresses the activation and effector function of CD4+ and CD8+ T cells [12-14]; thus, activating Tregs by blocking CTLA-4 may further impair the ability of T cells to keep viral hepatitis suppressed [15]. On the other hand, HCV viral replication is associated with “exhausted” CD8+ T cells, which express immune-inhibitory receptors, such as CTLA-4 and Programmed Death-1 (PD-1) (see Figure 1; [16]). Blockade of one or more of these immune checkpoints has demonstrated a decrease in HCV viral load and a reversal of HCV-specific T cell exhaustion which may stimulate an antiviral response [6,17-19]. Indeed, this phenomenon may underlie the decrease in viral load observed after administration of ipilimumab in case #3, described above. A similar mechanism may have led to the activation and proliferation of tumor-specific T cells, culminating in a durable anti-tumor response.

Autoimmune hepatotoxicity is a side effect of ipilimumab and of immune checkpoint inhibitors as a class. In a phase III trial combining ipilimumab with dacarbazine as first-line therapy for advanced melanoma, 78 of 247 (31.6%) patients who received both drugs experienced grade three or four immune-mediated hepatitis [3]. Of note, because dacarbazine monotherapy can cause hepatotoxicity, interpretation of these results was challenging. In a study of twenty one patients with hepatocellular carcinoma and chronic hepatitis C who received tremelimumab, another CTLA-4 blocking antibody, 45% experienced a transient grade three or higher rise in liver transaminases after the first dose [17]. Similarly, evidence of drug-related hepatic toxicity has also been reported with PD-1 antibodies [20,21]. In lieu of these risks, recommendations for administration of ipilimumab include monitoring of hepatic function tests prior to each dose and the rapid initiation of corticosteroid therapy in patients with ≥ grade 3 elevations of hepatic transaminases that are unrelated to melanoma progression [9]. In such patients, some investigators assess levels of serum autoimmune markers such as anti-nuclear antibodies, anti-smooth muscle antibodies and anti-nuclear cytoplasmic antibodies. Two of the nine
patients, described in this report, both of whom had chronic HCV infection, experienced fluctuations in LFTS and were treated with corticosteroids. Although this is a small series, the rate of hepatotoxicity appears similar to what was seen in the general population treated with ipilimumab, and the ability to administer ipilimumab did not appear to be affected by concomitant hepatitis B or C infection.

There remain limited published data describing the safety of ipilimumab administration to patients with metastatic melanoma who have pre-existing hepatitis B or C infection. Careful attention to baseline hepatic function and additional comorbidities is critical, as is close monitoring of LFT trends while patients are receiving therapy and consultation with specialists in chronic liver disease. As in patients treated with chemotherapy, patients with Hepatitis B infection may be candidates for concomitant HBV suppression with antiviral therapies, an additional risk mitigation strategy. Although a concomitant diagnosis of HBV or HCV is not an absolute contraindication to the administration of ipilimumab, a more thorough characterization of the drug’s effect on hepatitis, in particular viral load suppression, requires further evaluation in prospective studies.

Consent
Written informed consent was obtained from the patients for publication of this Case series. A copy of the written
consent is available for review by the Editor-in-Chief of this journal.

**Abbreviations**

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CT: Computed tomography; CTLA-4: Cytotoxic T Lymphocyte Antigen-4; HBc: Hepatitis B core Antibody; anti-HBc: Hepatitis B e-Antibody; HBeAg: Hepatitis B e-Antigen; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; IFNα: Interferon α; IL-2: Interleukin-2; LFTs: Liver function tests; MRI: Magnetic resonance imaging; PR: Partial response; PCR: Polymerase chain reaction; PET: Positron emission tomography; PD-1: Programmed Death-1; PD: Progressive disease; SD: Stable disease; Treg cells: T regulatory.

**Competing interests**

MR would like to disclose employment by and shareholder of Bristol Myers Squibb. HB would like to disclose employment by and shareholder of Bristol Myers Squibb. KS would like to disclose participation as a Speakers Bureau member for Bristol Myers Squibb. The remaining authors declare that they have no competing interests.

**Authors’ contributions**

SR contributed to the conception and coordination of the case series, data acquisition, drafting and final revision of the manuscript. KS contributed to the conception and coordination of the case series, data acquisition, figure design, drafting and final revision of the manuscript. NG participated in data acquisition and final revision of the manuscript. JIL participated in data acquisition and final revision of the manuscript. JAT participated in data acquisition and final revision of the manuscript. JMM contributed to the conception and coordination of the case series, data acquisition, table design and final revision of the manuscript. RK participated in data acquisition and final revision of the manuscript. NTG contributed to the data acquisition and drafting of the manuscript. JMM contributed to the conception and coordination of the case series, data acquisition and final revision of the manuscript. EJL participated in the conception and coordination of the case series, data acquisition, figure design, drafting and final revision of the manuscript. All authors read and approved the manuscript.

**Acknowledgements**

We thank Michael Usher, MD for help in developing and formatting the T cell tolerance figure included in this article. We thank Dr. Helena Brett-Smith, We thank Dr. Michael Usher, MD for help in developing and formatting the T cell tolerance figure included in this article. We thank Dr. Helena Brett-Smith, We thank Dr. Michael Usher, MD for help in developing and formatting the T cell tolerance figure included in this article. We thank Dr. Helena Brett-Smith, We thank Dr. Michael Usher, MD for help in developing and formatting the T cell tolerance figure included in this article. We thank Dr. Helena Brett-Smith.

**Authors details**

1. The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 1550 Orleans St., Rm. 507, Baltimore, MD 21287, USA. 2. Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA. 3. Bristol-Myers Squibb, Oncology Global Clinical Research, Route 206 and Province Road, Princeton, NJ 08543, USA. 4. Dana-Farber Cancer Institute Melanoma Disease Center, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA. 5. Dana-Farber Cancer Institute Melanoma Disease Center, Center for Immunology, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA. 6. Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave. East, Seattle, WA 98109, USA. 7. Division of Hematology/Oncology, Medical University of South Carolina, 173 Ashley Ave., Basic Science Building, Suite 102, Charleston, SC 29425, USA. 8. The Winship Cancer Institute of Emory University School of Medicine, 1365 Clifton Road, Atlanta, Georgia 30322, USA. 9. Bristol-Myers Squibb. Oncology Medical Strategy, 777 Scudders Mill Road, Plainsboro, NJ 08536, USA.

Received: 18 June 2014 Accepted: 15 August 2014

**Published online:** 14 October 2014

**References**

1. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J: Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (ipi) plus dacarbazine (DTIC) on Phase 3 study CA184-024. Ann Oncol 2012, 23:367–367.
2. Hodj FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassell JC, Akerley W, van den Eertwegh AI, Lutzky J, Longan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quit F, Clark JJ, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Utba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711–723.
3. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, JG, Selmen M, Lotem M, Harmanikaya K, Ibrahim S, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517–2526.
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg J, JH, Pile, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299–307.
5. Torres HA, Davila M: Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012, 9:156–166.
6. Minter S, Willner I, Shiral I. Ipilimumab-induced hepatitis C virus infection. J Clin Oncol 2013, 31:e307–e308.
7. Sharma A, Thompson JA, Reapa A, Melnichuk JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013, 31:e370–e372.
8. Lipson EI, Drake CG: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17:6958–6962.
9. Weber JS, Kahler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2011, 30:2691–2697.
10. Yeo W, Zee B, Zhong S, Chan PK, Wong W, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associated with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90:3106–3111.
11. Lau KC, Leung YH, Fong DT, Au KY, Kwong YL, Lie A, Hou JL, Wen YM, Nantji L, Liang H: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2003, 99:2324–2330.
12. Bancher-Allan C, Brown JA, Freeman GJ, Haffner DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245–1253.
13. Camara NO, Sebille F, Lechler R: Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 2003, 33:2473–2483.
14. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 2008, 8:525–532.
15. Stoop JN, van der Molen RG, Baan CC, Van Der L, Luc JW, Kuipers EJ, Kusters JG, Janssen LH: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771–778.
16. Wherry EJ. T cell exhaustion. Nat Immunol 2011, 12:492–499.
17. Sangro B, Gomez-Martín C, De La Mata M, Iñarraiaragui M, Gallardé E, Barrera P, Riezu-Boj JI, Larrea E, Añorbe C, Sarohe P, Lasarte J, Pérez-Gracia JL, Melero I, Prieto J: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013, 59:81–88.
18. Nakamoto N, Cho H, Shaked A, Othoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM: Synergistic reversal of intrahepatocellular HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313.
19. Gardiner D, Laleczan J, Lawitz E, DiMicco M, Ghall R, Reddy RR, Chang KM, Sukowki M, Marco SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selmy M, Kornan AJ, Lowy IA: A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 2013, 8:e63818.
20. Tolipalian SL, Hodj FS, Braham JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvalho RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Fardoll DM, Chen L, Sharfnan WH, Anders RA,
Ravi et al. *Journal for ImmunoTherapy of Cancer* 2014, 2:33
http://www.immunotherapyofcancer.org/content/2/1/33

Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Smol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012, 366:2443–2454.

21. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Alsaikhi-Schaap J, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with Lambrolizumab (Anti-PD-1) in Melanoma. *N Engl J Med* 2013, 369:134-144.

doi:10.1186/s40425-014-0033-1

Cite this article as: Ravi et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. *Journal for ImmunoTherapy of Cancer* 2014 2:33.